Related references
Note: Only part of the references are listed.Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores
Jihyun Kim et al.
LEUKEMIA & LYMPHOMA (2018)
An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma
Hugo J. A. Adams et al.
SEMINARS IN ONCOLOGY (2017)
C-MYC-Positive Relapsed and Refractory, Diffuse Large B-Cell Lymphoma: Impact of Additional Hits and Outcomes With Subsequent Therapy
Narendranath Epperla et al.
CANCER (2017)
The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma
Yan Yang et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2017)
Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?
Steven Le Gouill et al.
BLOOD (2017)
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
Qing Ye et al.
ONCOTARGET (2016)
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma
Anne-Segolene Cottereau et al.
CLINICAL CANCER RESEARCH (2016)
Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-D-glucose PET/CT in diffuse large B-cell lymphoma
S. H. Kwon et al.
CLINICAL RADIOLOGY (2016)
Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL
N. George Mikhaeel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring
Ryogo Minamimoto et al.
RADIOLOGY (2016)
18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
Karen Juul Mylam et al.
LEUKEMIA & LYMPHOMA (2015)
The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma
Sarah J. Nagle et al.
CANCER MEDICINE (2015)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou et al.
BLOOD (2014)
F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma
Rosj Gallicchio et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era
Deok-Hwan Yang et al.
ANNALS OF HEMATOLOGY (2013)
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Heike Horn et al.
BLOOD (2013)
Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma
Silvia Fuertes et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
Emmanuel Itti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
Carlo Visco et al.
HAEMATOLOGICA (2013)
The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma
Silvia Park et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy
Stephen M. Ansell et al.
MAYO CLINIC PROCEEDINGS (2012)
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
Rene -Olivier Casasnovas et al.
BLOOD (2011)
Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma
Deok-Hwan Yang et al.
EUROPEAN JOURNAL OF CANCER (2011)
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story
A. Bari et al.
ANNALS OF ONCOLOGY (2010)
Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background
Emmanuel Itti et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma
J. Y. Y. Ngeow et al.
ANNALS OF ONCOLOGY (2009)
Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma
Nozomi Niitsu et al.
CANCER SCIENCE (2009)
Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2008)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)